Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 8/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468286 | 0.88 | CYP3A4 (0.44) | CTSLCYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL6062798 | 0.87 | CTSL (0.52) | PSMB1CTSLCTSKCTSBCTSS | |
| SCHEMBL6061626 | 0.84 | PSMB1 (0.47) | PSMB1PSMB5PSMB2CTSLCTSK | |
| SCHEMBL6062730 | 0.78 | CYP3A4 (0.44) | PSMB1PSMB5PSMB2CTSLCTSK | |
| SCHEMBL6062618 | 0.77 | PSMB1 (0.44) | PSMB1PSMB5PSMB2CTSLCTSK | |
| SCHEMBL6462564 | 0.76 | PSMB1 (0.47) | PSMB1PSMB5PSMB2CTSLCTSK | |
| SCHEMBL6468287 | 0.74 | CYP3A4 (0.48) | CTSLCYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL7344658 | 0.71 | PSMB1 (0.52) | PSMB1PSMB5PSMB2CTSLCTSK | |
| SCHEMBL10045812 | 0.71 | MAPT (0.60) | POLB | |
| SCHEMBL7345357 | 0.70 | PSMB1 (0.51) | PSMB1PSMB5PSMB2CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | PSMB1 188/4885PSMB5 230/4885PSMB2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.